This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
AxoGen, Inc. (OTCBB: AXGN), a leading regenerative medicine company focused on the development and commercialization of products and technologies for peripheral nerve reconstruction and regeneration, announced today that it will hold its Annual Shareholders’ Meeting on Thursday August 30th, 2012. The meeting will take place at 1:00 p.m. Central Time at the following location:
Marriot Minneapolis West
9960 Wayzata Boulevard
St. Louis Park, MN 55426
Participants may also attend the meeting virtually via the Internet link
www.virtualshareholdermeeting.com/axogen. The Meeting will include an introduction, adjournment and Company overview provided by Karen Zaderej, Chief Executive Officer of AxoGen, and formal business matters presided over by Greg Freitag, Chief Financial Officer and General Counsel.
The Proxy Statement, with the accompanying Notice of Annual Meeting, and 2011 Annual Report on Form 10–K are available on the Company’s website at
Shareholders of record of the Company’s common stock at the close of business on July 9, 2012 will be entitled to receive notice of and to vote at the Meeting.
About AxoGen, Inc.
AxoGen (OTCBB: AXGN) is a leading regenerative medicine company with a portfolio of proprietary products and technologies for peripheral nerve reconstruction and regeneration. Every day, people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body and their damage can result in the loss of function and feeling. In order to improve surgical reconstruction and regeneration of peripheral nerves, AxoGen has developed and licensed patented and patent-pending technologies, which are used in its portfolio of products. This portfolio includes Avance
® Nerve Graft, a commercially available allograft nerve for bridging nerve discontinuities (a gap created when the nerve is severed) of 5mm to 70mm in length. Avance® Nerve Graft is sterilized and processed using a patented cleaning process that preserves the inherent and relevant structural characteristics of the tissue, allowing regenerating axons to grow through the scaffold to the motor or sensory organ.
AxoGen’s portfolio also includes AxoGuard
® Nerve Connector, a coaptation aid allowing for close approximation of severed nerves, and AxoGuard
® Nerve Protector, a bioscaffold used to reinforce a coaptation site, wrap a partially severed nerve or isolate and protect nerve tissue.
AxoGen is bringing the science of nerve repair to life with thousands of surgical implants of AxoGen products performed in hospitals and surgery centers across the United States, including military hospitals serving U.S. service men and women.